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heart reduction dose when comparing ABC to FB. Analysis was 
performed with BIOPLAN (BiOlogical evaluation of PLANs) PC 
based user-friendly software (evaluation of Dmax, Dmin, 
Dmean) and home-made Planning Reporting Orienteering 
(PRO)-DVH software. PRODVH produced Bio-DVH (Equivalent 
Dose Volume histograms for 25 fractions) that allowed the 
comparison regardless of the treatment schedule and that 
were used to calculate the average DVH for each set up. 
Secondary endpoints included dose reduction to the lung and 
procedural success rate. 
 
Results: Between May 2012 to February 2015, 50 patients 
with LBC are selected for receiving RT using ABC after both 
FB and ABC simulation. Procedural success was good, all 
patients have sufficient compliance and are been selected for 
this procedure. The primary endpoint was achieved: use of 
ABC reduced LAD/heart exposition (p < 0.01 T-student test). 
There was no significant difference between the free-
breathing and moderate deep inspiration breath-holding in 
the target volume coverage. The volume of the ipsilateral 
lung in the free-breathing technique was smaller than the 
moderate deep inspiration breath-holding techniques. All 
these data were confirmed with both software. 
 
Conclusion: ABC was well tolerated and significantly reduced 
heart/LAD dose without impairment in target volume 
coverage. No difference was find in lung dose reduction. Use 
of the ABC device during RT should be considered to reduce 
the risk of ischemic heart disease in populations at risk. 
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Purpose or Objective: Proper multi-atlas automated 
delineation can streamline clinical routine only when the 
proposed volume determination reasonably approximates the 
manual delineation. In this investigation we aimed to 
evaluate the automatic atlas-based segmentation of 
supraclavicular and level 3 lymph nodes for loco-regional 
irradiation of breast cancer. Further analysis were performed 
on the final plan’s dose coverage to the automated clinical 
target volume. 
 
Material and Methods: Between June and September 2015 
five consecutive breast cancer patients with clinical 
indication for loco-regional irradiation were selected. Pre-
defined breast delineation atlas of Mirada RTx (version 1.6.2, 
Mirada Medical, Oxford, United Kingdom) software were used 
to generate automated clinical target volumes (CTVauto) 
including the supraclavicular and the axillary level 3 lymph 
nodes. Responsible radiation oncologist delineated the 
reference CTV (CTVref) for each individual patients as well. 
Comparison metrics of Dice similarity (DI) and commonly 
contoured volume (CCV) were used. Furthermore the 
CTVauto was expanded with 1,2,3,4 and 5 mm uniform 
margin consecutively followed by an evaluation of the 
volumetric coverage of CTVref. Finally clinical plans were 
created expanding CTVref with 5 mm uniform margin using 
either direct antero-posterior beam or multi-beam IMRT. 
Dose coverage of the 95% of prescribed dose (V95) were 
compared for both CTVs. 
 
Results: The average CTVref was 35.1 cc (Standard deviation 
= 10.2), while for the CTVauto 42.1 cc (SD = 12.1). Mean DI 
and CCV were 0.73 (SD: 0.26) and 0.72 (SD: 0.28) 
respectively. Expanding the CTVauto up to 5 mm in 1 mm 
increments covered the CTVref with 53.9%, 77.9%, 88.1%, 
90.9% , 92.7% and 95.7% respectively. (Figure 1). For two 
patients single direct ante-posterior (AP) beam were used for 
the loco-regional treatment, while for the other three cases 
6 beam IMRT were used. Average V95% dose coverage of 
CTVref was 98.5% (SD: 3.0) which lowered to 92.0% (SD: 9.1%) 
for CTVauto. For the two patient with single AP field the 
CTVref were 93.0% and 99.5%, which dropped to 79.8% and 
99.4% for CTVauto. The multi-beam IMRT cases showed 100%, 
99.9% and 99.8% CTVref_V95 and 100%, 88.5% and 94.0% 
CTVauto_V95. 
 
 
 
Conclusion: CTV delineation using an atlas-based auto-
segmentation shows promising results even in a small 
complicated volume delineation such as the loco-regional 
lymph nodes of breast. Further improvement of the 
delineation accuracy is expected by adding more cases to the 
initial multi-atlas (with 3 provided cases). 
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Purpose or Objective: Locally advanced breast cancer 
(LABC), clinically classified as cT4, is mostly identified in 
elderly patients, typically featuring unfavorable prognosis. It 
is usually associated with ulceration, bleeding and local pain, 
with prolonged course. Radiation therapy (RT) shows an 
important role in local control and symptomatic control. 
Hypofractionation radiotherapy scheme, with a dose of 13 Gy 
in two fractions with an interval of 48 hours (also known as 
RT-FLASH), allows acceptable results. With this study we aim 
to evaluate the response of the patients treated with RT-
FLASH. 
 
Material and Methods: LABC patients treated from 2001 to 
2015 with RT-FLASH were retrospectively included. Local 
response was clinically assessed. Kaplan-Meier method was 
used for locoregional progression-free survival (LPFS) and 
overall survival (OS) analysis. Type I error of 0.05. 
 
Results: 63 patients were included, with a median age of 78 
years (39-92 years), 61.9% with Karnofsky ≤80% and median 
progression time of 13.5 months (2-180 months). Carcinoma 
not otherwise specified (NOS) was the most common 
histological type (84.1%), with estrogen receptor-positive in 
71.4%. Most of the tumors were cT4b (50.8%) and cT4c 
(36.5%) with cN+ in 60.3% and cM1 in 44.4%. At the initial 
evaluation 46.0% had bleeding injuries. Two RT-FLASH were 
performed in 65.1% of the patients. During treatment there 
was no record of toxicity. There was reduction of bleeding 
(81.5%), size (69.8%) and ulceration (39.6%). Surgical 
conditions were acquired in 23.8% of the patients. Patients 
cM1 received chemotherapy more often than cM0 (57.7% vs. 
17.6%; p=0.001). Of the 63.9% patients that received 
hormone therapy (HT), 77.5% had 2 RT-FLASH (p=0.002 vs. 
non-HT), with a greater dimensional reduction in patients 
undergoing HT (81.1% vs 43, 8%, p = 0.010). LPFS at 2 and 5 
years was 76.6% and 66.1%, respectively. The 2-year OS was 
39.7% and 5-year OS was 19.5%, higher in cM0 patients 
(p<0.001), patients subjected to 2 RT- FLASH (p=0.003), or 
under HT (p=0.001). Multivariate analysis showed significant 
